These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 29993360)
1. Short-term Outcomes in Patients with Carcinoma of the Esophagus and Gastroesophageal Junction Receiving Neoadjuvant Chemotherapy or Chemoradiation before Surgery. A Prospective Study. Nusrath S; Thammineedi SR; Vijaya Narsimha Raju KV; Patnaik SC; Pawar S; Santa A; Rajappa SJ; Mallavarapu KM; Raju K; Murthy S Rambam Maimonides Med J; 2019 Jan; 10(1):. PubMed ID: 29993360 [TBL] [Abstract][Full Text] [Related]
2. A Comparison Between Neoadjuvant Chemotherapy and Neoadjuvant Chemoradiotherapy in Treating Esophageal Carcinoma: A Study at a Tertiary Care Cancer Center in Suburban India. Shewalkar BK; Boralkar AK; Kaldate A; Shewalkar M Cureus; 2022 Jul; 14(7):e26674. PubMed ID: 35949733 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for initially unresectable locally advanced colon cancer: short-term outcomes of an open-label, single-centre, randomised, controlled, phase 3 trial. Zhang ZT; Xiao WW; Li LR; Wu XJ; Wang QX; Chang H; Tian X; Jiang W; Lin JZ; Zhang RX; Fan WH; Pan ZZ; Zhang R; Gao YH EClinicalMedicine; 2024 Oct; 76():102836. PubMed ID: 39364270 [TBL] [Abstract][Full Text] [Related]
4. Preoperative Concurrent Chemoradiotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: Phase II Randomized Study. Wang X; Zhao DB; Yang L; Chi Y; Zhao H; Jiang LM; Jiang J; Tang Y; Li N; Liu WY; Dou LZ; Zou SM; Xue LY; Ren JS; Tian YT; Che X; Guo CG; Bai XF; Sun YM; Wang SL; Song YW; Liu YP; Fang H; Li YX; Jin J Front Oncol; 2022; 12():870741. PubMed ID: 35574368 [TBL] [Abstract][Full Text] [Related]
5. To compare neoadjuvant concurrent chemo-radiotherapy followed by surgery and neoadjuvant chemotherapy followed by surgery in carcinoma esophagus patients: A single institutional study in the Indian population. Purkayastha A; Sharma N; Sundaram V; Jaiswal P; Husain A J Cancer Res Ther; 2023; 19(3):675-683. PubMed ID: 37470593 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial. von Döbeln GA; Klevebro F; Jacobsen AB; Johannessen HO; Nielsen NH; Johnsen G; Hatlevoll I; Glenjen NI; Friesland S; Lundell L; Yu J; Nilsson M Dis Esophagus; 2019 Feb; 32(2):. PubMed ID: 30137281 [TBL] [Abstract][Full Text] [Related]
7. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer. Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540 [TBL] [Abstract][Full Text] [Related]
9. Survival after neoadjuvant approaches to gastroesophageal junction cancer. Xiang M; Chang DT; Heestand GM; Pollom EL Gastric Cancer; 2020 Jan; 23(1):175-183. PubMed ID: 31230228 [TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576 [TBL] [Abstract][Full Text] [Related]
11. The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer - A systematic review. Hakeem AR; Papoulas M; Menon KV Eur J Surg Oncol; 2019 Feb; 45(2):83-91. PubMed ID: 30287098 [TBL] [Abstract][Full Text] [Related]
12. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction]. Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A; Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683 [TBL] [Abstract][Full Text] [Related]
15. Post-neoadjuvant chemoradiotherapy tumor resectability following induction chemotherapy in locally advanced proximal gastric and adenocarcinoma of the esophagogastric junction: A clinical trial. Aledavood SA; Anvari K; Shahidsales S; Hosseini S; Emadi Torghabeh A; Masudian M Caspian J Intern Med; 2021 Apr; 12(3):256-262. PubMed ID: 34221274 [TBL] [Abstract][Full Text] [Related]
16. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer. Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728 [TBL] [Abstract][Full Text] [Related]
17. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010 [TBL] [Abstract][Full Text] [Related]
18. Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus. Münch S; Pigorsch SU; Feith M; Slotta-Huspenina J; Weichert W; Friess H; Combs SE; Habermehl D Radiat Oncol; 2017 Nov; 12(1):182. PubMed ID: 29157271 [TBL] [Abstract][Full Text] [Related]
19. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer. Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852 [TBL] [Abstract][Full Text] [Related]
20. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Akita H; Takahashi H; Ohigashi H; Tomokuni A; Kobayashi S; Sugimura K; Miyoshi N; Moon JH; Yasui M; Omori T; Miyata H; Ohue M; Fujiwara Y; Yano M; Ishikawa O; Sakon M Eur J Surg Oncol; 2017 Jun; 43(6):1061-1067. PubMed ID: 28389044 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]